Cargando…
Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer
Gemcitabine has been used as a key drug for the treatment of pancreatic ductal adenocarcinoma. Although surgery remains the mainstay for cure of this lethal disease, the effect is quite limited, even for resectable disease, if there is no collaboration with chemotherapy. In the cases with unresectab...
Autor principal: | Motoi, Fuyuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992446/ https://www.ncbi.nlm.nih.gov/pubmed/35582385 http://dx.doi.org/10.20517/cdr.2021.75 |
Ejemplares similares
-
“From chemo to chemo”—the temporal paradox of chemotherapy
por: Moskalewicz, Marcin, et al.
Publicado: (2021) -
Preoperative gemcitabine based chemo-radiotherapy in locally advanced non metastatic pancreatic adenocarcinoma
por: Maximous, Doaa W, et al.
Publicado: (2009) -
Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance
por: Saiki, Yuriko, et al.
Publicado: (2020) -
Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling
por: Wu, Xiaoqing, et al.
Publicado: (2016) -
Targeting the translational machinery to overcome apoptosis resistance in pancreatic cancer
por: Wirth, Matthias
Publicado: (2022)